1/9/2023 8:23:16 AM
Neurocrine Biosciences, Voyager Therapeutics Collaborate For Development Of Voyager's GBA1 Program
12/14/2022 7:09:12 AM
Voyager Therapeutics Appoints Grace Colón To Board
9/7/2022 7:46:01 AM
Voyager Therapeutics Appoints Peter Pfreundschuh As CFO; Todd Carter As Chief Scientific Officer
3/22/2022 7:20:07 AM
Voyager Therapeutics Appoints Alfred Sandrock As CEO
3/8/2022 3:20:37 AM
Voyager Therapeutics Announces License Option Deal With Novartis For TRACER AAV Capsids For Gene Therapy Programs
10/6/2021 7:23:29 AM
Voyager Therapeutics Announces Licensing Agreement With Pfizer
5/27/2021 8:12:57 AM
Voyager Digital Announces Initiation Into The Blockchain Association
6/18/2019 6:29:23 AM
Wedbush Is Cutting Voyager Therapeutics (VYGR) FY19 Estimate To -3.59 From -3.19
6/18/2019 6:29:11 AM
Wedbush Is Cutting Voyager Therapeutics (VYGR) Q4 19 Estimate To -1.07 From -0.80
6/18/2019 6:28:51 AM
Wedbush Is Lowering Voyager Therapeutics (VYGR) Q2 19 Estimate To -0.91 From -0.78
6/18/2019 6:28:19 AM
Wedbush Reiterates Voyager Therapeutics (VYGR) At Outperform With $36 Up From $27 Price Target